SHIONOGI & CO., LTD.

ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor "Dolutegravir"

Osaka, Japan, September 4, 2014 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that the UK-based company, ViiV Healthcare Ltd. (Head Office: London; Chief Executive Officer: Dr. Dominique Limet) has issued a press release on September 3, 2014, regarding the marketing authorization for Triumeq®, an anti-HIV single-pill regimen containing the HIV integrase inhibitor dolutegravir, by the European Commission. Dolutegravir is currently approved and launched in the US, EU, Japan and other countries (Product name; Tivicay®) for the treatment of HIV infection in adults and adolescents.

Triumeq® containing dolutegravir plus abacavir and lamivudine (nucleoside reverse transcriptase inhibitors) provides one tablet, once-daily treatment for patients with HIV. This single-pill regimen has been approved by the United States Food and Drug Administration (FDA) on August 22, 2014. With this marketing authorization by the European Commission, Triumeq® will become available as an innovative and convenient treatment option for people living with HIV also in each member state of the European Union.

Shionogi is very pleased that this milestone has been achieved and will continue to work to maximize the value of Tivicay®, Triumeq® and the other integrase inhibitor assets of ViiV Healthcare as a shareholder.

Forward-looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications
Shionogi & Co., Ltd.
Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596
Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099